vs
爱德华生命科学（EW）与埃培智集团（IPG）财务数据对比。点击上方公司名可切换其他公司
埃培智集团的季度营收约是爱德华生命科学的1.3倍（$2.1B vs $1.6B），爱德华生命科学净利率更高（23.1% vs 5.8%，领先17.3%），爱德华生命科学同比增速更快（16.7% vs -4.8%），过去两年爱德华生命科学的营收复合增速更高（9.7% vs -9.1%）
爱德华生命科学是总部位于美国加利福尼亚州尔湾的医疗科技企业，专注于人工心脏瓣膜及血流动力学监测领域，其研发的Sapien经导管主动脉心脏瓣膜采用牛组织材质，搭配球囊扩张式钴铬合金支架，可通过导管完成植入。
埃培智集团（IPG）是总部位于美国纽约的广告营销传播集团，旗下拥有FCB、IPG盟博、麦肯世界集团、睿狮集团等五大核心业务网络，以及公关、体育营销、艺人经纪、医疗营销等领域的多家专业独立代理商，被宏盟收购前是与WPP、阳狮、宏盟齐名的全球广告行业“四大集团”之一。
EW vs IPG — 直观对比
营收规模更大
IPG
是对方的1.3倍
$1.6B
营收增速更快
EW
高出21.5%
-4.8%
净利率更高
EW
高出17.3%
5.8%
两年增速更快
EW
近两年复合增速
-9.1%
损益表 — Q1 FY2026 vs Q3 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.6B | $2.1B |
| 净利润 | $380.7M | $124.2M |
| 毛利率 | 78.0% | — |
| 营业利润率 | 1.8% | 10.3% |
| 净利率 | 23.1% | 5.8% |
| 营收同比 | 16.7% | -4.8% |
| 净利润同比 | 6.8% | 517.9% |
| 每股收益（稀释后） | $0.66 | $0.34 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EWIPG
| Q1 26 | $1.6B | — | ||
| Q4 25 | $1.6B | — | ||
| Q3 25 | $1.6B | $2.1B | ||
| Q2 25 | $1.5B | $2.2B | ||
| Q1 25 | $1.4B | $2.0B | ||
| Q4 24 | $1.4B | $2.4B | ||
| Q3 24 | $1.4B | $2.2B | ||
| Q2 24 | $1.4B | $2.3B |
净利润EWIPG
| Q1 26 | $380.7M | — | ||
| Q4 25 | $91.2M | — | ||
| Q3 25 | $291.1M | $124.2M | ||
| Q2 25 | $333.2M | $162.5M | ||
| Q1 25 | $358.0M | $-85.4M | ||
| Q4 24 | $385.6M | $344.5M | ||
| Q3 24 | $3.1B | $20.1M | ||
| Q2 24 | $366.3M | $214.5M |
毛利率EWIPG
| Q1 26 | 78.0% | — | ||
| Q4 25 | 78.1% | — | ||
| Q3 25 | 77.8% | — | ||
| Q2 25 | 77.5% | — | ||
| Q1 25 | 78.7% | -3.2% | ||
| Q4 24 | 78.9% | 10.1% | ||
| Q3 24 | 80.6% | 2.9% | ||
| Q2 24 | 79.9% | 1.2% |
营业利润率EWIPG
| Q1 26 | 1.8% | — | ||
| Q4 25 | 9.6% | — | ||
| Q3 25 | 19.8% | 10.3% | ||
| Q2 25 | 26.8% | 11.2% | ||
| Q1 25 | 27.9% | -2.1% | ||
| Q4 24 | 22.6% | 23.3% | ||
| Q3 24 | 25.9% | 5.9% | ||
| Q2 24 | 26.8% | 13.7% |
净利率EWIPG
| Q1 26 | 23.1% | — | ||
| Q4 25 | 5.8% | — | ||
| Q3 25 | 18.7% | 5.8% | ||
| Q2 25 | 21.7% | 7.5% | ||
| Q1 25 | 25.3% | -4.3% | ||
| Q4 24 | 27.8% | 14.1% | ||
| Q3 24 | 226.7% | 0.9% | ||
| Q2 24 | 26.7% | 9.2% |
每股收益（稀释后）EWIPG
| Q1 26 | $0.66 | — | ||
| Q4 25 | $0.16 | — | ||
| Q3 25 | $0.50 | $0.34 | ||
| Q2 25 | $0.56 | $0.44 | ||
| Q1 25 | $0.61 | $-0.23 | ||
| Q4 24 | $0.65 | $0.92 | ||
| Q3 24 | $5.13 | $0.05 | ||
| Q2 24 | $0.61 | $0.57 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $1.5B |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | — | $3.7B |
| 总资产 | — | $17.0B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资EWIPG
| Q1 26 | — | — | ||
| Q4 25 | $4.2B | — | ||
| Q3 25 | $3.8B | $1.5B | ||
| Q2 25 | $4.1B | $1.6B | ||
| Q1 25 | $3.9B | $1.9B | ||
| Q4 24 | $4.0B | $2.2B | ||
| Q3 24 | $4.4B | $1.5B | ||
| Q2 24 | $2.0B | $1.5B |
股东权益EWIPG
| Q1 26 | — | — | ||
| Q4 25 | $10.3B | — | ||
| Q3 25 | $10.2B | $3.7B | ||
| Q2 25 | $10.5B | $3.7B | ||
| Q1 25 | $10.1B | $3.6B | ||
| Q4 24 | $10.0B | $3.8B | ||
| Q3 24 | $9.5B | $3.7B | ||
| Q2 24 | $7.4B | $3.8B |
总资产EWIPG
| Q1 26 | — | — | ||
| Q4 25 | $13.7B | — | ||
| Q3 25 | $13.3B | $17.0B | ||
| Q2 25 | $13.5B | $17.0B | ||
| Q1 25 | $13.0B | $17.1B | ||
| Q4 24 | $13.1B | $18.3B | ||
| Q3 24 | $13.0B | $17.1B | ||
| Q2 24 | $10.1B | $17.0B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $180.1M |
| 自由现金流经营现金流 - 资本支出 | — | $153.6M |
| 自由现金流率自由现金流/营收 | — | 7.2% |
| 资本支出强度资本支出/营收 | — | 1.2% |
| 现金转化率经营现金流/净利润 | — | 1.45× |
| 过去12个月自由现金流最近4个季度 | — | $806.8M |
8季度趋势，按日历期对齐
经营现金流EWIPG
| Q1 26 | — | — | ||
| Q4 25 | $450.9M | — | ||
| Q3 25 | $573.7M | $180.1M | ||
| Q2 25 | $290.2M | $-96.0M | ||
| Q1 25 | $280.4M | $-37.0M | ||
| Q4 24 | $-127.5M | $868.1M | ||
| Q3 24 | $351.8M | $223.8M | ||
| Q2 24 | $371.5M | $120.7M |
自由现金流EWIPG
| Q1 26 | — | — | ||
| Q4 25 | $353.5M | — | ||
| Q3 25 | $516.2M | $153.6M | ||
| Q2 25 | $240.9M | $-121.8M | ||
| Q1 25 | $224.4M | $-58.5M | ||
| Q4 24 | $-177.3M | $833.5M | ||
| Q3 24 | $299.9M | $186.5M | ||
| Q2 24 | $286.1M | $85.9M |
自由现金流率EWIPG
| Q1 26 | — | — | ||
| Q4 25 | 22.5% | — | ||
| Q3 25 | 33.2% | 7.2% | ||
| Q2 25 | 15.7% | -5.6% | ||
| Q1 25 | 15.9% | -2.9% | ||
| Q4 24 | -12.8% | 34.2% | ||
| Q3 24 | 22.1% | 8.3% | ||
| Q2 24 | 20.9% | 3.7% |
资本支出强度EWIPG
| Q1 26 | — | — | ||
| Q4 25 | 6.2% | — | ||
| Q3 25 | 3.7% | 1.2% | ||
| Q2 25 | 3.2% | 1.2% | ||
| Q1 25 | 4.0% | 1.1% | ||
| Q4 24 | 3.6% | 1.4% | ||
| Q3 24 | 3.8% | 1.7% | ||
| Q2 24 | 6.2% | 1.5% |
现金转化率EWIPG
| Q1 26 | — | — | ||
| Q4 25 | 4.94× | — | ||
| Q3 25 | 1.97× | 1.45× | ||
| Q2 25 | 0.87× | -0.59× | ||
| Q1 25 | 0.78× | — | ||
| Q4 24 | -0.33× | 2.52× | ||
| Q3 24 | 0.11× | 11.13× | ||
| Q2 24 | 1.01× | 0.56× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EW
暂无分部数据
IPG
| MDE | $619.0M | 29% |
| IAC | $574.9M | 27% |
| Other | $527.9M | 25% |
| SCE | $413.8M | 19% |
